Filing Flows › Alnylam Pharmaceuticals (ALNY) › Q3 2026 › vs Q2 2026
Alnylam Pharmaceuticals (ALNY) Q3 2026 vs Q2 2026 (quarter over quarter)
Alnylam Pharmaceuticals's revenue rose $167M (+13%) from $1.3B in Q2 2026 to $1.5B in Q3 2026. The biggest changes: Net product revenues +$166M (+15%); ONPATTRO +$1.1M (+6%); Total Rare +$101K (+0.1%). Operating margin 23.7% against 17.9% (+5.8 pts).
Alnylam Pharmaceuticals, Q3 2026: revenue $1.5B (+17% year over year), operating margin 23.7%, net earnings $2.2B, operating cash flow $341M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 23.7% | 17.9% | +5.8 pts |
| Net margin | 148.6% | 12.7% | +135.9 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| AMVUTTRA | $1.1B | $1.0B | $119M | +12% |
| Royalty revenue | $94.7M | $71.7M | $23.0M | +32% |
| GIVLAARI | $89.5M | $89.8M | −$277K | -0.3% |
| Net revenues from collaborations | $71.5M | $47.2M | $24.3M | +52% |
| OXLUMO | $52.5M | $52.1M | $378K | +0.7% |
| Net product revenues | $1.3B | $1.1B | $166M | +15% |
| Total Rare | $142M | $142M | $101K | +0.1% |
| ONPATTRO | $19.6M | $18.5M | $1.1M | +6% |
| Revenue | $1.5B | $1.3B | $167M | +13% |
| Operating profit | $346M | $231M | $114M | +49% |
| Costs & expenses | $1.1B | $1.1B | $52.8M | +5% |
| Pre-tax earnings | $296M | $178M | $118M | +66% |
| Other expense, net | $50.0M | $53.6M | −$3.6M | -7% |
| Cost of revenue | $362M | $298M | $63.5M | +21% |
| Research & development | $409M | $413M | −$4.6M | -1% |
| SG&A | $342M | $348M | −$5.9M | -2% |
| Income tax benefit | $1.9B | −$13.3M | $1.9B | — |
| Net earnings | $2.2B | $164M | $2.0B | 13× |
| Depreciation & amortization | $14.5M | $0 | $14.5M | — |
| Share-based compensation | $79.1M | $86.6M | −$7.5M | -9% |
Questions
How much did Alnylam Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Alnylam Pharmaceuticals's revenue rose $167M (+13%) from $1.3B in Q2 2026 to $1.5B in Q3 2026.
What drove Alnylam Pharmaceuticals's revenue change in Q3 2026?
Net product revenues +$166M (+15%); ONPATTRO +$1.1M (+6%); Total Rare +$101K (+0.1%).